BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12217190)

  • 21. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group.
    La Nasa G; Argiolu F; Giardini C; Pession A; Fagioli F; Caocci G; Vacca A; De Stefano P; Piras E; Ledda A; Piroddi A; Littera R; Nesci S; Locatelli F
    Ann N Y Acad Sci; 2005; 1054():186-95. PubMed ID: 16339665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are HLA antigens a risk factor for acute GVHD in thalassemic patients receiving HLA-identical stem cell transplantation?
    Mohyeddin Bonab M; Alimoghaddam K; Vatandoust S; Forouzia F; Jahani M; Ghavamzadeh A
    Transplant Proc; 2004 Dec; 36(10):3190-3. PubMed ID: 15686726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hematopoietic stem cell transplantation for beta-thalassemia major].
    Zhu W; Yang M; He Y
    Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):265-7. PubMed ID: 11798768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic stem cell transplantation for beta-thalassemia major: experience in south of Iran.
    Ramzi M; Nourani H; Zakernia M; Hamidian Jahromi AR
    Transplant Proc; 2004 Oct; 36(8):2509-10. PubMed ID: 15561298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
    Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
    Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors.
    Yamasaki S; Henzan H; Ohno Y; Yamanaka T; Iino T; Itou Y; Kuroiwa M; Maeda M; Kawano N; Kinukawa N; Miyamoto T; Nagafuji K; Shimoda K; Inaba S; Hayashi S; Taniguchi S; Shibuya T; Gondo H; Otsuka T; Harada M;
    Bone Marrow Transplant; 2003 Sep; 32(5):505-10. PubMed ID: 12942097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The helper T lymphocyte precursor (HTLp) frequency does not predict outcome after HLA-identical sibling donor G-CSF-mobilised peripheral blood stem cell transplantation.
    Healey G; Schwarer AP
    Bone Marrow Transplant; 2002 Sep; 30(6):341-6. PubMed ID: 12235517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A comparative study of unrelated donor bone marrow transplantation and peripheral blood stem cell transplantation for their therapeutic effects on leukemia].
    Fan ZP; Yang K; Liu QF; Sun J; Xu D; Zhang Y; Wei YQ; Ye CX; Jiang QL; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1494-7, 1512. PubMed ID: 17062361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases.
    Sohn SK; Kim DH; Kim JG; Sung WJ; Baek JH; Lee NY; Won DI; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jun; 72(6):430-6. PubMed ID: 15128422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
    Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
    Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Status of donor-recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients.
    La Nasa G; Littera R; Locatelli F; Giardini C; Ventrella A; Mulargia M; Vacca A; Orrù N; Orrù S; Piras E; Giustolisi G; Lisini D; Nesci S; Caocci G; Carcassi C
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1358-68. PubMed ID: 17950922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
    van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
    Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.